About Limenbio
Where you live should not determine whether you live
Limenbio is a Swiss MedTech company developing HIPPER, a simpler way to keep donor hearts viable for longer, so more patients can reach a transplant.
Our mission
Keep donor hearts viable for longer, simply and reliably.
Our goal
Make transplantation possible regardless of time and distance, starting with the heart.
Our story
Limenbio grew out of more than 15 years of research on preserving living tissue. What began in 2010 with cells and skin grafts led to whole-heart preservation in animal models and two peer-reviewed publications. Today, from Biopôle in Lausanne, we are taking HIPPER from the lab to the clinic.
Team
Uliana Shchelgacheva
CEO
Two-time founder in digital health and HR-tech, with 6 years in business development and more than 10 years in corporate finance (ACCA). MSc in Behavioural Science, London School of Economics. Leads Limenbio's strategy, partnerships and financing from Switzerland.
Dr Alexandr Ponomarev, MD, PhD
Co-founder & Chief Scientific Officer
Physician-scientist and MedTech founder with 3 patents and 2 PCT applications. Expert in translational medicine and biopreservation, he created the preservation concept behind HIPPER and has led its research since 2010.
+
Join our team
Engineer · Microfluidics · Lausanne
Experience in cardiovascular devices. Help us build the beta prototype of HIPPER.
Advisors
Prof. Piergiorgio Tozzi
Medical Advisor
Cardiac and vascular surgeon and former deputy chief at CHUV, Lausanne University Hospital. Former president of the National Scientific Society for Organ Transplantation. Inventor with 20 patents and two inventions on the market.
Anzhey Zhimbiev
Advisor, MedTech Innovation
CEO of LifeDX SA at Biopôle and member of Business Angels Switzerland. Track record in product development, regulatory strategy, manufacturing scale-up and international commercialisation.